Miist Therapeutics, an Alameda CA-based physics-based developer of inhaled medicines, raised $7M in funding.
Backers included Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First, and California Innovation Fund, among others.
The company intends to use the funds to accelerate its two active programs in migraine and smoking cessation.
Led by CEO Dalton Signor, Miist Therapeutics applies a physics-based approach to develop inhaled therapies that are faster acting and more effective than today’s standard of care. Its core technology is an inhaler that uses ultrasonic vibration to generate and deliver 2-micron aqueous drug particles to the peripheral lung, where they are instantly absorbed into the bloodstream. Using this novel approach, the company is developing new inhaled therapies that will deliver instant relief for some of the most common and debilitating conditions.
Miist has clinically validated its approach and is currently advancing two assets: MST-01 for the treatment of smoking addiction and MST-02 for the treatment of migraine. Phase 1 results for MST-01 demonstrate the speed of Miist’s therapies, with patients achieving 92% symptom relief in only 2 minutes post dosing.
FinSMEs
05/02/2025